Vaccines: a tool for spending smart

Effective vaccination programmes ease pressure on budgets and allow resources to focus on other healthcare areas and medical innovation

Find out how


Prevention First

Vaccination at the Heart of Public Health. Vaccines Europe calls on EU policy-makers to develop a comprehensive vaccination strategy through five core policy asks.

Read more

Vaccine Market Access in the EU

How long for a vaccine to reach European Population? 6,4 years is the median time lag between marketing authorisation and effective population access

Find out more

The vaccine industry
in figures

With 47% growth in R&D investment over the past eight years and over 70% of current R&D projects based on new antigens and new combinations, Vaccines Europe members highly contribute to innovation.

Find out more

An industry for healthy lives

As the EU-wide recognised vaccine industry stakeholder, Vaccines Europe represents major innovative research-based vaccine companies operating in Europe and is currently expanding to SMEs.
Find out more about our services, the opportunites we offer and how to become a member.

Find out how to become a member

Latest News


Vaccines Europe is recruiting a Policy Manager

2016 02 08 Written by Vaccines Europe


Job Description: 
The person appointed will be based in the Vaccines Europe/EFPIA Office in Brussels, Belgium and will report directly to the Vaccines Europe Executive Director. Read more…

Pascale Mauran appointed as new Vaccines Europe Vice-President

2016 02 02 Written by Vaccines Europe

Vaccines Europe is pleased to announce that Pascale Mauran, Vice-President for EU Vaccines Commercial Development at Pfizer, has been officially appointed as the new Vaccines Europe Vice-President. Pascale Mauran has been representing Pfizer on the Vaccines Europe Board for three years now and brings solid experience and expertise on vaccines to help driving the development of the Vaccines Europe for a life-long vaccination strategy in Europe. Pascale Mauran’s appointment as Vice-President will start immediately and is expected to run for two years. Vaccines Europe President Andrea Rappagliosi earlier stated  Read more…

Annual Health & Economic Benefits of Influenza Vaccination

2015 12 07 Written by Vaccines Europe

Influenza is a serious infectious disease with potentially serious consequences. Every year in the EU, the ECDC estimates that on average 40,000 premature deaths occur due to seasonal influenza. Globally this figure rises to 500,000 (WHO). Nevertheless, influenza can be prevented, achieving important health and economic benefits. These benefits can be optimised if the EU Member States were to reach the 75% vaccination coverage target agreed upon by the Council for the elderly and at risk groups. Read more…

See all News